Summation and synergism in the promotion of urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)-nitrosamine in F344 rats. 1984

T Sakata, and T Shirai, and S Fukushima, and R Hasegawa, and N Ito

Summation and synergism in the effects of three tumor promoters on urinary bladder carcinogenesis initiated by a 4-week treatment with 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in male F344 rats were examined. In experiment 1, the sequential administration of sodium saccharin (SS, 5.0%), DL-tryptophan (Tr, 2.0%) and sodium L-ascorbate (SA, 5.0%) in the diet, each for 10 weeks, significantly increased the incidence and the number of bladder tumors over that observed after SS alone or SS followed by Tr. In experiment 2, the simultaneous dietary administration of 2.5% SA, 1.0% butylated hydroxyanisole and 0.01% allopurinol for 32 weeks significantly increased the yield of bladder tumors. Paired combinations of promoters or each of the promoters administered alone were associated with a less pronounced promotive effect than when all three were combined. Thus, it is evident from the results of the present investigation that whatever the mechanisms underlying promotion by the different agents, they are capable of working in an additive fashion, under conditions of summation (consecutive administration) or synergism (simultaneous administration).

UI MeSH Term Description Entries
D006965 Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells. Hyperplasias
D008297 Male Males
D009602 Nitrosamines A class of compounds that contain a -NH2 and a -NO radical. Many members of this group have carcinogenic and mutagenic properties. Nitrosamine
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D001743 Urinary Bladder A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION. Bladder,Bladder Detrusor Muscle,Detrusor Urinae,Bladder Detrusor Muscles,Bladder, Urinary,Detrusor Muscle, Bladder,Detrusor Muscles, Bladder
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002083 Butylated Hydroxyanisole Mixture of 2- and 3-tert-butyl-4-methoxyphenols that is used as an antioxidant in foods, cosmetics, and pharmaceuticals. Butylhydroxyanisole,(1,1-Dimethylethyl)-4-methoxyphenol,AMIF-72,BHA,Butyl Methoxyphenol,Embanox,Nipantiox 1-F,Tenox BHA,AMIF 72,AMIF72,Hydroxyanisole, Butylated,Methoxyphenol, Butyl,Nipantiox 1 F,Nipantiox 1F
D002085 Butylhydroxybutylnitrosamine A substituted carcinogenic nitrosamine. Butylbutanolnitrosamine,N-Butyl-N-(4-hydroxybutyl)nitrosamine,N-Nitroso-N-butyl-(4-hydroxybutyl)amine,N-Nitrosobutyl-4-hydroxybutylamine,N Nitrosobutyl 4 hydroxybutylamine
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D000493 Allopurinol A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms. Allohexal,Allohexan,Alloprin,Allopurin,Allorin,Allpargin,Allural,Apulonga,Apurin,Atisuril,Bleminol,Caplenal,Capurate,Cellidrin,Embarin,Foligan,Hamarin,Jenapurinol,Lopurin,Lysuron,Milurit,Milurite,Novopurol,Pan Quimica,Progout,Pureduct,Purinol,Remid,Rimapurinol,Roucol,Suspendol,Tipuric,Uribenz,Uridocid,Uripurinol,Urosin,Urtias,Xanthomax,Xanturic,Zygout,Zyloprim,Zyloric

Related Publications

T Sakata, and T Shirai, and S Fukushima, and R Hasegawa, and N Ito
September 1992, Japanese journal of cancer research : Gann,
T Sakata, and T Shirai, and S Fukushima, and R Hasegawa, and N Ito
January 1993, Teratogenesis, carcinogenesis, and mutagenesis,
T Sakata, and T Shirai, and S Fukushima, and R Hasegawa, and N Ito
August 1987, Journal of the National Cancer Institute,
T Sakata, and T Shirai, and S Fukushima, and R Hasegawa, and N Ito
June 1994, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,
T Sakata, and T Shirai, and S Fukushima, and R Hasegawa, and N Ito
September 1984, Gan,
T Sakata, and T Shirai, and S Fukushima, and R Hasegawa, and N Ito
November 1991, Japanese journal of cancer research : Gann,
T Sakata, and T Shirai, and S Fukushima, and R Hasegawa, and N Ito
January 1984, Journal of cancer research and clinical oncology,
T Sakata, and T Shirai, and S Fukushima, and R Hasegawa, and N Ito
August 1986, Cancer letters,
T Sakata, and T Shirai, and S Fukushima, and R Hasegawa, and N Ito
January 1986, Urological research,
Copied contents to your clipboard!